647 related articles for article (PubMed ID: 22925430)
21. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
Wada S; Fukawa T; Kamiya S
Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
[TBL] [Abstract][Full Text] [Related]
22. [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].
Quemerais-Durieu MA; Kerlan V; Chabre O
Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S15-22. PubMed ID: 22008272
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological management of osteogenesis.
Nardone V; D'Asta F; Brandi ML
Clinics (Sao Paulo); 2014 Jun; 69(6):438-46. PubMed ID: 24964310
[TBL] [Abstract][Full Text] [Related]
24. Future therapeutic targets in osteoporosis.
Deal C
Curr Opin Rheumatol; 2009 Jul; 21(4):380-5. PubMed ID: 19461517
[TBL] [Abstract][Full Text] [Related]
25. The use of PTH in the treatment of osteoporosis.
Borba VZ; Mañas NC
Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):213-9. PubMed ID: 20485911
[TBL] [Abstract][Full Text] [Related]
26. [Novel strategies for the development of anabolic agents for treatment of osteoporosis].
Saeki M; Egusa H
Nihon Yakurigaku Zasshi; 2014 Dec; 144(6):277-80. PubMed ID: 25492363
[No Abstract] [Full Text] [Related]
27. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
Ishtiaq S; Fogelman I; Hampson G
J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
[TBL] [Abstract][Full Text] [Related]
28. Anti-resorptive therapies for osteoporosis.
Reid IR
Semin Cell Dev Biol; 2008 Oct; 19(5):473-8. PubMed ID: 18760372
[TBL] [Abstract][Full Text] [Related]
29. Bone-forming agents in the management of osteoporosis.
Neuprez A; Reginster JY
Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):869-83. PubMed ID: 19028361
[TBL] [Abstract][Full Text] [Related]
30. Osteoanabolic and dual action drugs.
Tabacco G; Bilezikian JP
Br J Clin Pharmacol; 2019 Jun; 85(6):1084-1094. PubMed ID: 30218587
[TBL] [Abstract][Full Text] [Related]
31. Anabolic effects of intermittent PTH on osteoblasts.
Greenfield EM
Curr Mol Pharmacol; 2012 Jun; 5(2):127-34. PubMed ID: 21787293
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of anabolic therapies for osteoporosis.
Canalis E; Giustina A; Bilezikian JP
N Engl J Med; 2007 Aug; 357(9):905-16. PubMed ID: 17761594
[No Abstract] [Full Text] [Related]
33. Anabolic therapy in glucocorticoid-induced osteoporosis.
Sambrook PN
N Engl J Med; 2007 Nov; 357(20):2084-6. PubMed ID: 18003966
[No Abstract] [Full Text] [Related]
34. Anabolic therapies for osteoporosis.
Uihlein AV; Leder BZ
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
[TBL] [Abstract][Full Text] [Related]
35. [Potential use of parathyroid hormone (PTH) in the treatments for oral diseases].
Tanaka S; Hata K; Yoneda T
Clin Calcium; 2012 Jan; 22(1):75-82. PubMed ID: 22201102
[TBL] [Abstract][Full Text] [Related]
36. Emerging anabolic treatments in osteoporosis.
Mosekilde L; Tørring O; Rejnmark L
Curr Drug Saf; 2011 Apr; 6(2):62-74. PubMed ID: 21524248
[TBL] [Abstract][Full Text] [Related]
37. Combination anabolic and antiresorptive therapy for osteoporosis.
Cusano NE; Bilezikian JP
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):643-54. PubMed ID: 22877434
[TBL] [Abstract][Full Text] [Related]
38. Parathyroid hormone as an anabolic skeletal therapy.
Rubin MR; Bilezikian JP
Drugs; 2005; 65(17):2481-98. PubMed ID: 16296873
[TBL] [Abstract][Full Text] [Related]
39. Anti-resorptives in the management of osteoporosis.
Miller PD
Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):849-68. PubMed ID: 19028360
[TBL] [Abstract][Full Text] [Related]
40. Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis.
Cosman F; Nieves JW; Dempster DW
J Bone Miner Res; 2017 Feb; 32(2):198-202. PubMed ID: 27925287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
